IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VERNIERI, CLAUDIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.854
NA - Nord America 1.252
AS - Asia 581
OC - Oceania 11
SA - Sud America 8
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.714
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.209
DE - Germania 806
CN - Cina 374
GB - Regno Unito 347
IT - Italia 308
SE - Svezia 185
IE - Irlanda 58
IN - India 53
CA - Canada 41
HK - Hong Kong 38
DK - Danimarca 29
FR - Francia 25
JP - Giappone 22
FI - Finlandia 21
UA - Ucraina 21
SG - Singapore 18
TR - Turchia 14
BE - Belgio 13
AU - Australia 11
NL - Olanda 11
VN - Vietnam 11
ID - Indonesia 10
PH - Filippine 10
KR - Corea 9
TW - Taiwan 8
IR - Iran 7
CH - Svizzera 6
RO - Romania 6
RU - Federazione Russa 6
BR - Brasile 5
UZ - Uzbekistan 4
PL - Polonia 3
AP - ???statistics.table.value.countryCode.AP??? 2
EG - Egitto 2
GR - Grecia 2
HU - Ungheria 2
MU - Mauritius 2
MX - Messico 2
NO - Norvegia 2
AR - Argentina 1
EC - Ecuador 1
ES - Italia 1
GH - Ghana 1
IL - Israele 1
MY - Malesia 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 3.714
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 721
Southend 306
Chandler 194
Fairfield 117
Ashburn 115
Milan 109
Wilmington 76
Houston 75
Seattle 58
Dublin 55
Princeton 55
Ann Arbor 52
Dearborn 49
Woodbridge 44
Beijing 42
Cambridge 40
Nanjing 37
Hanover 34
Toronto 31
Jinan 28
Bengaluru 26
Redwood City 24
Des Moines 23
Shenyang 22
Shanghai 21
Phoenix 19
Hong Kong 18
Helsinki 17
Berlin 15
Central District 15
Changsha 14
Tianjin 14
Brussels 13
Hangzhou 13
Hebei 13
Guangzhou 11
Chengdu 10
Nanchang 10
Zhengzhou 10
Silver Spring 9
Hefei 8
New York 8
San Diego 8
Fremont 7
Kunming 7
Mountain View 7
Rome 7
Wuhan 7
Boardman 6
Grafing 6
London 6
Naples 6
Seoul 6
Bologna 5
Bucharest 5
Central 5
Chicago 5
Falls Church 5
Madignano 5
Redmond 5
Serio 5
Taipei 5
Taizhou 5
Buffalo 4
Cagliari 4
Haikou 4
Indianapolis 4
Monza 4
Mumbai 4
Napoli 4
Ottawa 4
São Paulo 4
Voghera 4
Amsterdam 3
Cornate d'Adda 3
Duncan 3
Groningen 3
Hiroshima 3
Istanbul 3
Los Angeles 3
Merate 3
Nantes 3
Newcastle 3
Ningbo 3
Padova 3
Parma 3
Tokyo 3
Turin 3
Baotou 2
Blacksburg 2
Boston 2
Brugherio 2
Bühl 2
Cairo 2
Cantu 2
Casorate Primo 2
Catania 2
Chiari 2
Delhi 2
Erlangen 2
Totale 2.803
Salva come PNG Salva come JPEG
Nome #
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 289
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC 185
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer 173
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 167
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma : the FAME Trial 166
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) 163
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 160
THE INTERPLAY BETWEEN CDK1/CLBS AND PP2A/CDC55 IN ADAPTATION TO THE SPINDLE ASSEMBLY CHECKPOINT (SAC) 153
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 150
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up 149
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers 142
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies 139
Targeting cancer metabolism : Dietary and pharmacologic interventions 125
Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-l1 monoclonal antibodies 120
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. 119
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles 112
Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis 107
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives 103
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State 100
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes 97
Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process 96
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders 94
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study 88
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer 86
Diet and supplements in cancer prevention and treatment : clinical evidences and future perspectives 84
Update on medical treatment of small intestinal neuroendocrine tumors 83
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting 82
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab 63
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 60
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors 52
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 41
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 39
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study 38
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 38
The impact of COVID-19 on diagnosis of recurrent breast cancer 36
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters 6
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 1
Totale 3.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201964 0 0 0 0 0 0 0 0 0 0 21 43
2019/2020619 62 16 16 75 46 76 58 46 91 75 21 37
2020/2021463 30 30 28 23 24 44 34 47 59 35 42 67
2021/2022699 53 60 60 43 43 49 48 54 70 75 35 109
2022/2023659 78 97 58 55 54 127 29 48 55 12 32 14
2023/20241.098 26 32 37 33 108 51 264 208 104 204 31 0
Totale 3.906